Clin2
NCT07473960Possibly a fitActive, not recruiting

A new medicine for high cholesterol and mixed high lipids

Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Part of Genetic & congenital, Hormones & metabolism clinical trials.

This study tests a new medicine (IBI306) for people with high LDL cholesterol (between 2.6 and 4.9 mmol/L) and high triglycerides (up to 5.64 mmol/L). It is for those without a history of heart disease or diabetes, and who are at low to moderate risk for heart problems over the next 10 years.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
198 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Age is between 18 and 75 years old.
  • Your LDL (bad) cholesterol is between 2.6 and 4.9 mmol/L.
  • Your triglycerides (another type of fat in blood) are below 5.64 mmol/L.
  • Your 10-year risk of a heart attack or stroke is less than 10%.
  • You do not have known heart disease, diabetes, or other serious medical conditions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07421284Not yet recruiting· Phase 3
Study of SYH2053 for high cholesterol in Chinese adults

This trial tests a new investigational medicine (SYH2053) for people with high cholesterol or mixed hyperlipidemia who are already on cholesterol-lowering therapy but still have high levels of 'bad cholesterol' (LDL-C). The goal is to see if this add-on treatment can help lower cholesterol further and reduce heart disease risk.

Beijing, Beijing Municipality
NCT07421297Recruiting· Phase 3
Study of SYH2053 for high cholesterol in Chinese adults

This trial tests a new medication called SYH2053 for people with high cholesterol or mixed high cholesterol and triglycerides. If you have high LDL cholesterol and are not taking strong cholesterol medicines, you may be able to join. The study will see if this drug is safe and works well.

Beijing, Beijing Municipality
NCT05621070Recruiting· Phase 3
Test drug JS002 for high cholesterol not at goal

This Phase 3 study tests whether JS002 alone can lower LDL “bad” cholesterol in people whose levels are still too high for their heart-risk level. It will also check how safe the treatment is, especially for heart and metabolic side effects.

Beijing, Beijing Municipality
NCT07615296Not yet recruiting
Ultra-low cholesterol targets for very high-risk heart disease

This study tests whether lowering cholesterol to very low levels (below 1.0 mmol/L) is more beneficial and safe than a slightly higher target (1.0–1.39 mmol/L) in patients with severe, recurrent heart or stroke events. You'll receive cholesterol-lowering medications and regular monitoring to see which target works best.

Beijing, Beijing Municipality
NCT07444086Not yet recruiting· Phase 3
A study of a new medicine for high cholesterol

This trial tests if a new drug, QLC7401, can lower cholesterol in people with high cholesterol who are not on other cholesterol medicines. It may be an option if you have low or medium risk of heart disease and no history of heart problems.

NCT07441317Not yet recruiting· Phase 3
Testing a new drug for stubborn high cholesterol

This trial tests a new medication (QLC7401) for people with high cholesterol that is not well controlled by their current treatment. It aims to see if the drug can help lower LDL-C (bad cholesterol) levels and reduce the risk of heart problems.

Hear when a new Non-familial Hypercholesterolemia and Mixed Hyperlipidemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.